Navigation Links
Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress
Date:2/25/2008

gy. It is a small- molecule inhibitor of lipoprotein-associated phospholipase-A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques and identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK is developing darapladib as a treatment for atherosclerosis, and it has the potential to be an important treatment for the prevention of cardiovascular risk. HGS will receive a 10% royalty on worldwide sales if darapladib is commercialized, and also has a co-promotion option in North America and Europe, under which it would pay 20% of commercialization costs in exchange for 20% of darapladib profits. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance darapladib to Phase 3 development.

Syncria(R): 2008 Phase 3 Decision Possible

In May 2007, GSK initiated a randomized Phase 2b dose-ranging clinical trial of Syncria (albiglutide) in patients with type 2 diabetes. As a comparison, one group of patients is receiving Byetta (exenatide).

Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology. Syncria is generated from the genetic fusion of human albumin and GLP-1, a peptide hormone that acts throughout the body to help maintain normal blood sugar levels and to control appetite. GSK is developing Syncria as a treatment for type 2 diabetes mellitus. HGS is entitled to fees and milestone payments, some of which have already been received, that could amount to as much as $183 million, in addition to royalties on worldwide sales if Syncria is commercialized. HGS believes it is possible that GSK will reach a decision in 2008 regarding whether to advance Syncria to Phase 3 development.

HGS-XENCOR ANTIBODY COLLABORATION

On February 7, 2008, HGS and Xencor, Inc. announced a collaboration agreement under which Xencor will apply its proprietary technologies
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Bill Jacobs Automotive, a group of car dealerships headquartered in ... Heartland Blood Center and offering free oil change coupons for ... Saturday, Jan. 18 at the Bill Jacobs Cadillac and Chevrolet ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto ...
(Date:1/15/2014)... 2014   Niagara Thermal Products is proud to ... Technologies LLC ("B3") as the critical thermal component supplier ... the Army Corps of Engineers.  B3 has developed the ... contaminants and destroys VOCs and other chemical pollutants, allergens ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... 20 Cardium Therapeutics (NYSE Amex: CXM ... and Chief Executive Officer will present at the 10th ... September 29-30, 2010 at the Radisson Blu Hotel in ... can access a replay of the Company,s recent presentation ...
... ... if (typeof(lpUnit)==,undefined,) var ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
... energy could be a central alternative to petroleum-based energy ... the same energy yield and is more expensive to ... solar energy production on the environment is incomplete, experts ... benefits and detriments of solar power, a research team ...
Cached Biology Technology:Cardium to Present at 10th Annual Biotech in Europe Investor Forum 2China-Biotics Hosted its First Investor Day Event 2China-Biotics Hosted its First Investor Day Event 3China-Biotics Hosted its First Investor Day Event 4China-Biotics Hosted its First Investor Day Event 5China-Biotics Hosted its First Investor Day Event 6China-Biotics Hosted its First Investor Day Event 7China-Biotics Hosted its First Investor Day Event 8Research team assesses environmental impact of organic solar cells 2
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
(Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
... Sept. 16, 2008 Researchers at UT Southwestern ... electrical stimulation of nerves by outfitting electrodes with ... of basic black, formed from carbon nanotubes. ... transmitted by electrodes, which researchers say is a ...
... CORVALLIS, Ore. More than 125 years ago Charles Darwin ... the night, not the day and this week, scientists ... phenomenon. These rhythmic growth spurts, and the ability of ... by genes involved in circadian rhythms the "biological clock" ...
... Scientists have discovered that certain fish are capable of ... includes striking images of fish fluorescing vivid red ... sunlight by sea-water, objects which look red under normal ... This has contributed to the belief among marine biologists ...
Cached Biology News:Coating improves electrical stimulation therapy used for Parkinson's, depression, chronic pain 2'Biological clock' genes control plant growth 2
...
... member of Wyatt Technology's family of light ... your high temperature chromatograph and enables you ... thermoplastic polymers. The HTmD is easily installed ... PL220C or Alliance 2000 device and enables ...
...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. PROTECT ... A cell-permeable sulfanamido-benzbromarone compound that acts ... allosteric inhibitor of PTP1B (IC 50 ... μM for PTP1B 403 and ...
Biology Products: